FDA Approval For BioLineRx Multiple Myeloma Treatment

BioLineRx (Nasdaq: BLRX) has received FDA approval for APHEXDA™ (motixafortide) in combination with filgrastim (G-CSF) to mobilize hematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in patients with multiple myeloma.

APHEXDA is the first innovation in stem cell mobilization for multiple myeloma to be approved in the U.S. in a decade.

Philip Serlin, Chief Executive Officer of BioLineRx, said, “We believe APHEXDA will play a critical role in addressing unmet needs and introduce a new treatment paradigm for this challenging cancer. The company is working relentlessly to make this important innovation in stem cell mobilization available to appropriate patients, their physicians and transplant teams.”

Highlights

The FDA approval of APHEXDA is based on results from the 2-part, Phase 3 GENESIS trial, a randomized, double-blind, placebo-controlled study

One dosage of APHEXDA plus filgrastim enabled a majority of patients to achieve the collection goal of ≥ 6 million hematopoietic stem cells among a contemporary population of multiple myeloma patients.

BioLineRx expects to make APHEXDA available later this month.

Multiple myeloma is an incurable blood cancer that affects some white blood cells called plasma cells, which are found in the bone marrow. In 2023, it is estimated that more than 35,000 people will be diagnosed with multiple myeloma, and nearly 13,000 people will die from the disease in the United States.

Autologous stem cell transplantation (ASCT) is part of the standard treatment paradigm for a number of blood cancers, including multiple myeloma. Treatment success depends on adequate mobilization of stem cells during the treatment process.

About BioLineRx

BioLineRx Ltd. (NASDAQ/TASE: BLRX) is a commercial stage biopharmaceutical company pursuing life-changing therapies for certain cancers and rare diseases. The company’s first approved product is APHEXDA™ (motixafortide) with an indication in the U.S. for stem cell mobilization for autologous transplantation in multiple myeloma. BioLineRx is advancing a pipeline of investigational medicines for patients with sickle cell disease, pancreatic cancer, and other solid tumors. Headquartered in Israel, and with operations in the U.S., the company is driving innovative therapeutics with end-to-end expertise in development and commercialization, ensuring life-changing discoveries move beyond the bench to the bedside.

Share This Article

 

About the Author

FDA Approval For BioLineRx Multiple Myeloma Treatment

Catie Corcoran

Biotech Editor